Search Results
Your search for ,CNS matches 885 pages
Showing 801 - 850Long-Term Use of Hormonal Contraceptives Could Lead to Increased Risk of Brain Tumors
Taking a hormonal contraceptive for at least 5 years is associated with a possible increase in women’s risk of developing a glioma, according to a study by Andersen et al published in the British Journal of Clinical Pharmacology. Study Details While little is known about the causes of...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
FDA Approves Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) today approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. Lanreotide was previously approved for...
Germline SUFU Mutations Cause Gorlin Syndrome and Increase Risk for Childhood Medulloblastoma
In a study to identify causative mutations in patients with Gorlin syndrome without PTCH1 mutations, Smith et al found that germline mutations in SUFU were associated with Gorlin syndrome and with increased likelihood of Gorlin syndrome–associated childhood medulloblastoma. The study is...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
FDA Grants Orphan Drug Designation to DNX-2401 for Malignant Glioma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DNAtrix’s DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
New ALK Inhibitor Alectinib Shows Activity vs Crizotinib-Resistant NSCLC
In the phase I portion of a phase I/II study reported in The Lancet Oncology, Gadgeel et al found that the novel ALK inhibitor alectinib showed activity against systemic disease and brain metastases in patients with non–small cell lung cancer (NSCLC) resistant to the ALK inhibitor crizotinib...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to...
Pilot Study Evaluates Concurrent Use of Sunitinib and Radiation Therapy in Recurrent High-Grade Glioma
The combination of continuous daily-dosed sunitinib (Sutent) and hypofractionated stereotactic radiation therapy produced acceptable toxicity and “encouraging” 6-month progression-free survival in previously irradiated patients with recurrent high-grade glioma, according to the results...
FDA Grants Priority Review to Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsen’s supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA...
No Benefit of Adding Cilengitide in Glioblastoma With Methylated MGMT Promoter
In the phase III CENTRIC EORTC 26071-22072 trial reported in The Lancet Oncology, Stupp et al found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard temozolomide chemoradiotherapy produced no survival benefit in newly diagnosed glioblastoma...
Early Study Identifies Tumor-Suppressor Gene, Potential Therapy for Medulloblastoma
An international, multi-institutional research group led by scientists at the Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center has identified a novel molecular pathway that causes an aggressive form of medulloblastoma, The study, reported by He et al ...
ICML Imaging Working Group Issues Updated Guidelines on PET-CT for Staging and Response Assessment for FDG-Avid Lymphomas
Barrington et al in the International Conference on Malignant Lymphomas Imaging Working Group have presented updated consensus guidelines on 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)-computed tomography (CT) for staging and response assessment for FDG-avid lymphomas. The...
Body Mass Index Positively Associated With Many Cancers in UK Study
In a UK population-based cohort study of associations between body mass index (BMI) and 22 specific cancers reported in The Lancet by Bhaskaran et al, positive associations were found for most cancers and were strongest for uterine, gallbladder, kidney, cervix, thyroid, liver, colon, ovarian, and...
Study Detects New ALK Mutations at Neuroblastoma Relapse
In a study reported in the Journal of Clinical Oncology, Schleiermacher et al found ALK mutations at relapse of neuroblastoma that were not present at diagnosis. They also found that subclonal mutations may be present at diagnosis with clonal expansion observed at relapse. The study involved...
Successful Vemurafenib Treatment of Progressive BRAF V600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma
The BRAF inhibitor vemurafenib (Zelboraf) is approved for treatment of BRAF-mutated metastatic melanoma. There are reports indicating that vemurafenib may be active in the treatment of intracranial neoplasms with BRAF mutations. As reported in the Journal of Clinical Oncology, Lee et al from...
Improvements in Overall Survival in Trilateral Retinoblastoma Due to Improved Chemotherapy and Earlier Detection
In a systematic review and meta-analysis reported in The Lancet Oncology, de Jong et al found a dramatic improvement in overall survival among children with trilateral retinoblastoma since 1995, reflecting increased use of conventional and high-dose chemotherapy with stem cell rescue in pineal and...
Investigational Compound ABT-414 Receives Orphan Drug Designation for Glioblastoma Multiforme
The U.S. Food and Drug Administration has granted orphan drug designation to AbbVie’s investigational compound ABT-414, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. ABT-414 is an investigational anti-EGFR (epidermal growth factor receptor)...
Dutch Phase II Study Supports Phase III Evaluation of Bevacizumab Plus Lomustine, but Not Bevacizumab Alone, in Recurrent Glioblastoma
Bevacizumab (Avastin) is frequently used in patients with recurrent glioblastoma, although it is unclear whether responses observed with such treatment result in improved overall survival. In the phase II Dutch BELOB study reported in The Lancet Oncology, Taal et al found that overall survival...
Two Common Gene Variants Associated With Longer Telomere Length May Increase the Risk of Glioma
Two common gene variants that lead to longer telomere length may increase the risk of glioma, according to the results of a study presented by Walsh et al in Nature Genetics. This finding suggests that telomere length may prove to be a promising epidemiologic risk factor for cancer. It is well...
Lanreotide Significantly Prolongs Progression-Free Survival in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Although somatostatin analogs are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors, data on their antitumor effects are limited. In the phase III CLARINET trial reported in The New England Journal of Medicine, Caplin et al found that somatostatin...
Brain Tumor Invasion Along Blood Vessels May Lead to New Cancer Treatments, Preclinical Study Suggests
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain’s protective barrier, preclinical study published in Nature Communications indicated. The finding by Watkins et al could ultimately lead to new ways to bring about the ...
Preclinical Study Reveals Heparan Sulfate Suppresses Growth of Neuroblastoma
A heparin derivative differentiated cancer cells and caused neuroblastomas to regress without causing severe bleeding, according to the findings of a preclinical study presented in The Journal of Clinical Investigation. Knelson et al identified novel roles for heparan sulfate proteoglycans in...
Glioma-Associated Antigen Peptide Vaccination Produces Antigen-Specific T-Cell Response and Clinical Activity in Children With High-Grade Gliomas
In a study reported in the Journal of Clinical Oncology, Pollack et al found antigen-specific immune responses and evidence of clinical activity with glioma-associated antigen (GAA) peptide vaccination in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. Study Details In ...
Brain Tumor Risk Greater in Women Who Begin Menstruation at Older Age, Study Reports
Women who begin menstruation at an older age have a significantly increased risk of developing a brain tumor, a Moffitt Cancer Center study shows. The results are part of a large multicenter study to determine potential risk factors associated with the development of glioma and meningioma. The...
Survivors of Childhood Cancers Experience Frequent Hospitalizations Years After Cancer Treatment
Childhood and adolescent cancer survivors often face ongoing health problems that require frequent and long hospital stays many years after their cancer diagnosis and treatment, according to a new study by Kirchhoff et al published in Cancer Epidemiology, Biomarkers & Prevention. Survivors of...
ASCO 2014: Addition of Chemotherapy to Radiotherapy Improves Survival in Low-Grade Glioma
In a long-term follow-up analysis of RTOG 9802, the addition of PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) to radiotherapy prolonged both progression-free survival and overall survival in adult patients with low-grade glioma. The findings were reported at the 2014 ASCO Annual ...
Phase I Study Finds Novel Antibody Shows Promise in Children With Advanced Neuroblastoma
Researchers from St. Jude Children’s Research Hospital conducted a phase I study of hu14.18K322A, an experimental monoclonal antibody genetically engineered at the hospital, in 38 children with refractory or recurrent neuroblastoma. The patients received escalating doses of hu14.18K322A...
Modafinil Not Better Than Placebo for Fatigue in Lung Cancer Patients
In a trial reported in the Journal of Clinical Oncology, Spathis et al found that that the central nervous system (CNS) stimulant modafinil had no effect on fatigue compared with placebo in patients with advanced non–small cell lung cancer (NSCLC). Fatigue improved in both groups during the...
Gene Sequencing Project Discovers Mutations Tied to High-Grade Gliomas in Young Children
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric high-grade gliomas. The findings by Wu et al were published in Nature Genetics and may lead to improved outcomes for children with these brain...
Researchers Identify Transcription Factors Distinguishing Glioblastoma Stem Cells
The activity of four transcription factors appears to distinguish the small proportion of glioblastoma cells responsible for the aggressiveness and treatment resistance of the deadly brain tumor. The findings by Suvà et al, published online in Cell, support the importance of epigenetics in...
Deep, Integrated Genomic Analysis Reclassifies Lower-Grade Brain Tumors
Using comprehensive genomic analysis, researchers have sorted low-grade brain tumors into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors. The findings were reported at the American Association for Cancer...
18F-FDOPA PET Predicts Good Prognosis as Soon as 2 Weeks After Start of Antiangiogenic Therapy in Recurrent High-Grade Glioma
In a study reported in Clinical Cancer Research, Schwarzenberg et al found 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-FDOPA) positron-emission tomography (PET) metabolic tumor volume values at 2 weeks after the start of bevacizumab (Avastin) were highly predictive of outcome in patients with ...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment
Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...
Metastatic Neuroblastoma Confined to Distant Lymph Nodes Associated With Better Survival Compared With Other Stage IV Disease
The pattern of metastatic spread is not incorporated into current risk-stratification systems for neuroblastoma. In a retrospective study reported in the Journal of Clinical Oncology, Morgenstern et al found that patients with neuroblastoma with metastatic disease limited to distant lymph nodes...
Pemetrexed and Gemcitabine Show Promise Against Aggressive Childhood Brain Tumor
The quest to improve survival of children with a high-risk brain tumor has led investigators at St. Jude Children's Research Hospital to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers. The study by Morfouace at al was published today in Cancer Cell....
Erlotinib and Gefitinib Offer Similar Benefit in EGFR-Mutated Non–Small Cell Lung Cancer
A retrospective study has shown that two targeted therapy drugs—erlotinib (Tarceva) and gefitinib (Iressa)—achieved similar outcomes among people with metastatic or recurrent non–small cell lung cancer (NSCLC) harboring an EGFR mutation. These EGFR tyrosine kinase inhibitors have...
IDH1-Mutant Malignant Astrocytomas May Be More Amenable to Surgical Resection and Linked to Better Prognosis
IDH1 mutation in patients with malignant astrocytomas may serve as a predictive molecular biomarker to guide aggressive surgical resection, according to the results of a study reported by Beiko et al in Neuro-Oncology. Maximal surgical resection may contribute a survival benefit in those who have...
Blood Test Could Improve Treatment for Children With Late-Stage Neuroblastoma
Research by Viprey et al has found that the detection of neuroblastoma mRNAs in peripheral blood and bone marrow aspirates from children diagnosed with stage IV neuroblastoma are independent predictors of event-free survival and overall survival. Their findings could help identify children with...
Study Identifies Possible New Target for Future Glioblastoma Drugs
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by Yan et al published in Cancer Research. The findings show that high levels of the enzyme PRMT5...
Bevacizumab Added to Radiotherapy/Temozolomide Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Glioblastoma
In a double-blind phase III trial reported in The New England Journal of Medicine, Chinot et al assessed adding bevacizumab (Avastin) to radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. This was the second of two similar studies published in the February 20 issue of...
Adding Bevacizumab to Radiotherapy and Temozolomide Does Not Improve Overall Survival in Newly Diagnosed Glioblastoma
In a double-blind phase III trial reported in The New England Journal of Medicine, Gilbert et al assessed adding bevacizumab (Avastin), which is currently approved in recurrent glioblastoma, to radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. The addition of bevacizumab...
Study Identifies Common Driver of a Childhood Brain Tumor
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The findings were published online in...
Small Panel of FISH Cytogenetic Markers Distinguishes Risk in Medulloblastoma Subgroups
Among the four major molecular subgroups of medulloblastoma, WNT tumors are associated with excellent prognosis, whereas SHH and Group 4 tumors are associated with intermediate and Group 3 tumors with poor prognosis. In a study reported in the Journal of Clinical Oncology, Shih et al identified a...
Optimized Radiation Treatment Schedule for Glioblastoma May Extend Survival
An altered radiation treatment schedule for glioblastoma, the most common and lethal form of brain cancer, extended the survival period of mice with the disease, according to a new study published in Cell. Because the research involved mice, the study does not recommend a specific new schedule for...
Potential Therapeutic Role for Aspirin in the Management of Sporadic Vestibular Schwannoma
In patients with sporadic vestibular schwannoma, aspirin may be of benefit in minimizing tumor growth, according to the results of a retrospective study presented by Kandathil et al in Otology and Neurotology. This finding may eliminate the need for invasive therapy and may complement existing...
High Prevalence of Platinum-Related Hearing Loss in Children With High-Risk Neuroblastoma, With Differences According to Audiometry Scales
The reported prevalence of platinum-associated ototoxicity in children with high-risk neuroblastoma varies widely due to small patient samples and use of disparate grading scales. In a study reported in the Journal of Clinical Oncology, Landier et al in the Children’s Oncology Group assessed...
